A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications
International Journal of Molecular Sciences · 04.11.2026 · 27 (21) · 9870
DOI: 10.3390/ijms27219870 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.11.2026. Verfasst von Yinfei Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Complex molecular alterations in cancers influence tumor biology, therapeutic response, and resistance. We report a case of cutaneous melanoma demonstrating extensive intratumoral heterogeneity with important clinical implications. A 77-year-old man with stage IIA cutaneous melanoma developed an isolated nodal recurrence one year after resection. Comprehensive next-generation sequencing of the metastatic lesion revealed an uncommon genomic profile consisting of a class 3 BRAF Y472V mutation, two NF1 loss-of-function mutations, and two concurrent KIT mutations: a dominant, potentially targetable K642E mutation and a low-frequency D816V mutation associated with resistance to tyrosine kinase inhibitors. The tumor exhibited a high tumor mutational burden and microsatellite stability. The patient received neoadjuvant nivolumab plus relatlimab followed by surgical resection, achieving complete pathologic response. Repeat sequencing of the resected specimen demonstrated complete molecular clearance of all previously detected variants. This case illustrates the value of comprehensive genomic profiling in revealing biologically complex melanoma with coexisting driver and resistance-associated alterations. The presence of a treatment-naïve KIT resistance mutation suggests preexisting subclonal heterogeneity that may influence future targeted therapy, while high tumor mutational burden and NF1 loss may have contributed to the excellent response to immune checkpoint blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
- Department of Pathology, Temple University, Philadelphia, PA 19140, USA.
- Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
ORCID-Profile: Giuliana G Berardi, Anjali Seth, Anthony J Olszanski, Y Lynn Wang
Zitieren
APA
Tan, Y., Berardi, G. G., Guo, T., Seth, A., Olszanski, A. J., Wu, H., & Wang, Y. L. (2026). A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications. International Journal of Molecular Sciences, 27(21), 9870. https://doi.org/10.3390/ijms27219870
Vancouver
Tan Y, Berardi GG, Guo T, Seth A, Olszanski AJ, Wu H, et al. A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications. International Journal of Molecular Sciences. 2026;27(21):9870. doi:10.3390/ijms27219870
BibTeX
@article{Tan2026,
author = {Tan, Yinfei and Berardi, Giuliana G and Guo, Tingwei and Seth, Anjali and Olszanski, Anthony J and Wu, Hong and Wang, Y Lynn},
title = {A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9870},
doi = {10.3390/ijms27219870}
}
EUVIMED